SLC5A2 and hydrops fetalis: We found a significant association between SGLT-2 inhibition and reduced risk of HF (0.42 [0.30–0.59], P < 0.0001), achieved by a 1-standard deviation decrease in HbA1c through SGLT-2 inhibition (Table 1).